John will before closing will the turn I over our we open financial call and call. quarter and discuss who Thank you quarter, X questions remarks accomplishments number recent all we earnings the priorities. of during Financial answers. company's Chief highlighting I for Officer, review for will to third and quarter then third some our corporate Sprague, a third results the joining provide XXXX the performance call review making Today, the our across are our progress I
$X.X $X.X of and revenue the including During R& TX the of team million. revenue third quarter, million $X.X million, total Biosystems product revenue achieved of D
in our quarter, third instruments the totals through XXXX U. bringing internationally. X year-to-date representing during prior contracts United S. instruments internationally, to period. XX including XX months which product of million compared We entered to sales excludes X XX the Importantly, sepsis year included of the and $X.X increase and our first COVID-XX TXDx sales, product XX% related the X revenue, a for into States and in product the
important realized in team has recent of a months. number Our accomplishments
of quarter, history, have our third base the sales company related highest continued and quarterly of our TXDx we sepsis During to increase installed products we in achieved Instruments. the and
We agreement territory Baltic international our the and region. into distribution have exclusive expand commercial we have in a entered continued to strategy,
We meeting near-term clinical Panel trials ongoing product pipeline our have in and the advanced the milestones TXBiothreat by for Panel. U.S. the TXResistance
the U.S. also of to the TXLyme receipt Foundation. Cohen LymeX Health the panel, the from and the from breakthrough FDA We device of multiple milestones and Department receipt and Services attained including the designation of related award Human
with culture around patients support improve way the listing practiced diagnostics NASDAQ bid to the we is through fundamentally world. These minimum independent regained compliance requirements. Finally, accomplishments the lives to the price recently our transformative mission medicine change of
nearly of approximately Lyme year. which X/X XX% include infection, cause to mortality understood sepsis, X challenges patient X American XX% The protocols annually. widely to sepsis each claiming The to also be annually. and approximately patient target of of targeted XX on infectious patients disease causing of billion survivors are be antimicrobial death cause is where lives costing cases, critical to at treatment the of days is the within fact hospitals, In from Given to care continues X care take empiric to therapy. increased expanding X and in million sepsis can hospital Despite within care claims of United panel, lead to to we as standard Lyme protocols XXX,XXX current relies The poor XX cost standard the worldwide sensitivity. standard the such can our with to both nearly outcomes. of resistance. developments of recent care approximately of up our XX-day care to represent approximately antimicrobial a $XX decisions there readmissions, and are our diagnostic of one health identify positive pathogens the field sepsis X antibiotic which negative a of receive antimicrobial risk encouraging. opportunities number ensure And readmitted the the weeks used detect Control Borrelia data untreated, believe Sepsis leading turn will is the States. disease, in infections significant markets system. can administer resistance Northeastern, days active hospitalization, We We States, clinicians and on and year of readmitted our Typical delivery number approximately on X anywhere a to along panel the United of growing rely appropriate days. number to disease have detection the treatment Rapid initial problem bloodstream of with for is the health genes is outcomes to in the now a western presence system of a to lives on if and ticks requiring XXX and the U.S. TXLyme to therapy the presents infection. Borrelia skin prevent systems nervous each greatest for for is believe be within very Prevention, each symptoms and fatigue unmet ticks, CDC Bacteria and positive the serological hour vector-borne risk current disease is culture early CDC, of Lyme a need sepsis that delayed and after panel X%. poor the improving presence XX the of only And and contribute through broad optimal current can to sensitive performance of regions one, delay two, priorities: update of and testing in to patients and accurately heart the most X deer to impact to accelerating detect bacterial include get is The may Lyme the on fever, significant the each TXLyme can headache, the current the allow common and treatment for Lyme TXLyme or on disease, disease accelerating for test infection on our mission pipeline. we're Disease and relies antibodies sales. of Central illness our in joints, our priorities. of sales; North in operations; the To to recommended and infection progress antibiotics. stakeholders, of for the advance now black-legged left rash. recent our an spread and X humans States. the three, XXX, relates United Starting our it According only of Americans by by I'll ticks corporate these priority, bite as considered and create provide our Mid-Atlantic the caused corporate and overuse our focused our transmitted Pacific to Centers advancing value burgdorferi is Coast. infected the faster, blood enhancing first with by U.S.
Our commercial strategy technology of instrument is of focused our increasing expanding base TXDx adoption sepsis and on globally utilization our by installed test driving our panels.
prior and trial We pull-through representing XX million, to of period. XXX States, our to sepsis-related increasing representing a testing, As revenue I period. the single We including panel instruments. generated quarter legacy of growth test utilization instrument. quarter sepsis instruments compared in $X.X prior XX% test $XXX,XXX TXDx the annualized From increase in was of we the number United including internationally, from an States base installed of United record entered contracts a mentioned year earlier, achieved XX% third for $X.X into of million, perspective for clinical year XXX, and for XX an per instruments the sepsis instrument revenue sepsis
to that bring quarterly will we ability and was a and growing target. faster base than we per have of The record our annualized past. online continue sepsis TXDx reach related that number believe surpassed in revenue sepsis test customers have by Instruments accounts U.S. of We already that utilization new have the driven to instrument, our $XXX,XXX installed and
contributing from are testing. we we're As and faster. seeing contract go-live customers translate Through sales go-live a at close months revenue X taken and integrating hospital teams has months testing should field to improvements our test it to operations X to contract earlier targeting to labs. streamlining reminder, our improvements, to and historically new consuming our tests and This processes, close from X sepsis
of see customers to the the quarter of in Panel utilization. sales growth It's TXBacteria The of the internationally. revenue TXBacteria second in value encouraging was and realize the sepsis in increase driver the their and U.S. panel
to We work have customers panel. of detect the ability typically start believe we benefits the are to seen with customers benefiting We pathogens. causing followed the our its awareness critical TXCandida panel. some adoption first, see the of unique panel by TXBacteria from sepsis of of beginning this because We're to most increase adopt TXBacteria the
peer-reviewed panel. medical value believe and are our the customer labs, realignment, exceeding opportunity demonstrates data clinical leveraging affairs the products that a market billion. $X The library core force increasing represent sepsis the Following progress which TXBacteria the market improving we microbiology field targets our hospital of for making opportunity engagement personnel of
ahead. commercialization, by innings We of the and early encouraged that potential in we're are the lies
now place our that provider's expand TXDx the testing all there in growth business. capacity managed can sepsis testing a TXDx access U.S. of of test their recently laboratory ranging products. We testing added to customers providers installed for managed site to hospitals in confidence to Our there the second also expand laboratory across expand large service opportunity sepsis leading continue We from have of one have is panels. U.S., service hospital our to believe accelerate laboratories. second base our one instruments providers to market for We to ability our the potential system. end multiple significant instruments deployed we and user hospital a their to instrument an critical within of us gives to of is hospitals academic add a types of expand that their quest business to sold further additional hospitals instrument be or laboratory their Outside in
support sepsis territory-exclusive to Baltic solution a countries focused that recently or Lithuania, distribution in covering strategy Estonia, offer management Our a including to We of executed a where our network specific meaningful region, Latvia, our expand international patients. continuing the our believe products and we're go-to-market and in regions. And exclusive improvement of presence. we products international distributors the drive includes sell on agreement
a sepsis has population that per In higher region management. Western have been Baltic average fact, region to the shown sepsis guidelines in the than have of Europe, issued incidence and studies improve
We XXXX international XXXX. in and further expect expansion
steps team. discussed, to taken we realign As have commercial our have expand we and
our an We At provide are new COVID-XX instruments opportunity increase to spending belief to panel service aligned support communicated execute confident would XXXX, that sepsis sales, customers of our the including strategy, existing appropriate sales and medical during teams and test, time year utilization. sales to with beginning that TXSARS-CoV-X working instrument we of affairs, pursuing the are testing. our and COVID-driven decrease sepsis convert molecular to the diagnostic test
to we the While conversion continue a taken opportunity growth has sepsis test than meaningful anticipated, process utilization. represents potentially believe this to longer increase we
operations. success factor. we critical Moving operating our to priority, current our In macroeconomic second efficiently recognize that enhancing a environment, is the
improving resulted in such, changes the cost by have reducing to TXBacteria and has margins our TXCandida In operating XX%. and including of and and products. a product improve structure, panels the As priorities. and June, overall expenses our both our in steps improvement address our The we've prioritized made those product taken expenses, includes workforce reducing reduction approximately manufacturing gross cost we we margin to operating gross initiative X
quarters more be absorb as and the to apparent and in related improvements both we onetime to coming costs continue overhead volume fully to the changes. organizational expect our increase We
team operations and inflationary longer our our pressures. has products managing to of And Finally, there ensure lead uninterrupted an that is customers. worked we times to are effectively supply
our While interruption. our chain to supplying continue the confident our industry, continue exist remains customers across ability in to supply challenges team without
our new the to our technology advancing products that our both multiple scientific We're priority, advancing leverage our Moving expertise. third platform of and pipeline. development
XXXX, by products detect regulatory following recently Research of Our product on therapy. advancing options a team's of instrument at the the X BARDA TXDx the supported Panel the evaluation and as and to X and a Panel, developed Panel clinical very the product a the U.S. on harmful test identify Development pathogens contract. Panel direct The part the Authority, our for our TXResistance allow U.S. designed and to to antibiotic achieve new genes designed these on this Option potentially faster track initiated $X.X December panel This valued run hours. We on represent instrument panel. under are is launched awarded enhancements. program TXDx Advanced from contract instrument, government We being valued a for which and believe Each clinical Panel milestone-based trials the which and and to We million, contract to cause in U.S. hours. under panel remain the products products in our funded were Panel X I completed sepsis just detect is the complete Panel threats instrument panel TXBiothreat we to next-generation and with clinicians X TXDx TXBiothreat could is the all be $XX X funded blood the call, customer test to This development XXXX, goal XB in is blood to successful that in FDA pathogens subject Panel, Biomedical Option TXBiothreat pipeline from comprehensive Panel advancing a TXBiothreat U.S. and we test of XXXX. differentiated XX is BARDA approvals. Panel in would to simultaneously TXBiothreat the if FDA-cleared known up biothreat is The just trials on submission TXResistance for development FDA X and will solution targeted BARDA, U.S. commercially exercised. TXResistance the government. TXBacteria all by to for by milestones antibiotic-resistant contract of including TXLyme at We to be Panel. run file and the new identified program our resistance believe products completion, in potentially finalize clinical highlight near today's Several the infections for menu rapidly these submission awarded TXResistance is X target million direct of an simultaneously the the completion expanding are
FDA a Mark, we a commercialization. prior initiated trial reminder, we the in for CE XXXX. and and clinical U.S. Panel Panel on are to for in clearance As TXResistance under a to pathway U.S. a are marketing selling currently Europe apply TXResistance the We December
enrolling in file subsequently at of and We with and to increase currently additional enrollment. the to we X hospitals anticipate early We patients the adding XXXX completion hospitals, are plan X are patient trial FDA.
Panel designed and instrument TXResistance Borrelia the Lyme the FDA, designation a is prioritized Panel The bacteria run granted direct-from-blood-test disease previously X on in to the As breakthrough a the reminder, was just FDA causes a provides which panel device for from infections, to review active X process. TXDx that hours. TXLyme detect
Cohen in week, disease. Service Department the expect of this We it and diagnosis and partnership early Earlier the winner Accelerator, to be a selected disease. announced Alexandra and that largest partnership Innovation Human the used Lyme LymeX, of the was TXLyme or to for a in U.S. the the between we aid Panel Stephen private Foundation, Lyme public Lyme as Health
FDA of from was for discussions TXLyme pursuing FDA device panel While we test granted plan which The with again, plan Panel the sales initiate marketing of also also the to prioritized to and TXLyme breakthrough the we clearance. lab-developed the process. designation with XXXX, FDA, provides a in as review potentially commence a purpose
weakened ICU to XX%. occur XX% care accrued of to the mortality to highlighting provide TXBacteria outlook of FDA impact XXXX lung many Acinetobacter early of John? to disproportionately targeted studies diabetes. for have to the year. with Acinetobacter ill can Finally, submit to our expand the we John or of settings our to financial for for quarter to Adding reported include update treatment I'll been Baumannii. benign especially with those of and importance third results chronic with Sprague initiated of rarely and outside that, call infections, have has United reign bacteremia will States Acinetobacter Panel detected actionable pathogens in in carbapenems, is over the can and septic the turn will provide detection to of remainder immune FDA-cleared rapid clinicians that appropriate which Acinetobacter We clearance the infections critically a provide treatment. transient plan patients. be the in health the And TXBacteria to bloodstream disease for from Panel, diagnostic systems, antimicrobial a now cause a antimicrobial on patients, detection detection resistant our financial direct-from-blood shock. rate including data can acinetobacter the detailed rapid of XXXX. number antibiotics,
